EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SLC25A19 drives colorectal cancer progression by regulating p53

Jinbo Jiang, Xuemei Li, Jiayong Wang, Shaofei Chen, Lingjuan Chen iD

Cancer Medicine · 2024-09 · 13 (18)

DOI: 10.1002/cam4.70253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 30.09.2024. Verfasst von Jinbo Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tumor Suppressor Protein p53, Cell Proliferation, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, the Beijing Kechuang Medical Development Foundation Fund of China, Bethune-Cancer Radiotherapy Translational Medicine Research Fund of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Investigating the molecular mechanism of colorectal cancer (CRC), a common lethal malignancies worldwide, is of great clinical significance. Solute carrier family 25 member 19 (SLC25A19) is a member of the solute carrier family that contribute to cellular functions, including tumor biology. Recently, many studies have attention on uncovering the relationship of SLC25A19 with malignant cancers, but its precise involvement in the regulation of CRC has not been thoroughly understood. This study sought to uncover the role and mechanism of SLC25A19 in CRC development.

Methods

The GEPIA database and immunohistochemical staining were utilized to detect the expression of SLC25A19 in CRC tissues. The functional influences of SLC25A19 on CRC cell phenotypes were evaluated through a series of assays including celigo cell count, colony formation, CCK‐8, flow cytometry, wound healing, and transwell assays following knocking down SLC25A19. Subsequently, the xenograft tumor model was constructed to evaluate the effect of SLC25A19 on tumor growth in vivo. The underlying mechanisms of SLC25A19 silencing were investigated using the human phospho‐kinase array.

Results

This study demonstrated the upregulation of SLC25A19 in CRC and its significant correlation with unfavorable prognosis in CRC patients. Suppression of SLC25A19 resulted in significant inhibition of cell proliferation, colony formation, and cell migration, alongside a boost in cell apoptosis. In vivo experiments revealed that silenced SLC25A19 displayed reduced growth rates and formed smaller xenografts. Mechanistically, the p53 pathway was found to be upregulated by SLC25A19 knockdown and mediated the function of SLC25A19.

Conclusions

Consequently, SLC25A19 was identified as a novel molecule with key regulatory ability in CRC development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTumor Suppressor Protein p53Cell ProliferationGene Expression Regulation, NeoplasticDisease ProgressionHumansAnimalsMiceCell Line, TumorPrognosisApoptosisMice, NudeCell MovementFemaleMaleXenograft Model Antitumor AssaysMice, Inbred BALB C

Stichwörter der Autor:innen

SLC25A19apoptosiscolorectal cancerp53proliferation

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong, China.
  • Advanced Medical Research Institute, School of Medicine, Shandong University, Jinan, Shandong, China.
  • Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Lingjuan Chen

Förderung

  • Natural Science Foundation of Shandong Province
  • the Beijing Kechuang Medical Development Foundation Fund of China
  • Bethune-Cancer Radiotherapy Translational Medicine Research Fund of China

Zitieren

APA

Jiang, J., Li, X., Wang, J., Chen, S., & Chen, L. (2024). SLC25A19 drives colorectal cancer progression by regulating p53. Cancer Medicine, 13(18). https://doi.org/10.1002/cam4.70253

Vancouver

Jiang J, Li X, Wang J, Chen S, Chen L. SLC25A19 drives colorectal cancer progression by regulating p53. Cancer Medicine. 2024;13(18). doi:10.1002/cam4.70253

BibTeX
@article{Jiang2024,
  author = {Jiang, Jinbo and Li, Xuemei and Wang, Jiayong and Chen, Shaofei and Chen, Lingjuan},
  title = {SLC25A19 drives colorectal cancer progression by regulating p53},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {18},
  doi = {10.1002/cam4.70253}
}
Kostenlos starten →